# Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

> **NCT04579380** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 217 (actual)

## Conditions studied

- Uterine Neoplasms
- Uterine Cervical Neoplasms
- Biliary Tract Neoplasms
- Urologic Neoplasms
- Carcinoma, Non-Small-Cell Lung
- HER2 Mutations Breast Neoplasms

## Interventions

- **DRUG:** tucatinib
- **DRUG:** trastuzumab
- **DRUG:** fulvestrant

## Key facts

- **NCT ID:** NCT04579380
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-11
- **Primary completion:** 2023-11-01
- **Final completion:** 2026-04-30
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04579380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04579380, "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04579380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*